Journal article
Abstract P3-07-18: CCTG IND.239: A phase 2 study of combined CFI-400945 and durvalumab in patients with advanced triple negative breast cancer (aTNBC)
Abstract
Abstract
CCTG IND.239: A phase 2 study of combined CFI-400945 and durvalumab in patients with advanced triple negative breast cancer (aTNBC) John Hilton, David W. Cescon, Andrew Robinson, Sukhbinder Dhesy-Thind, Sara Kristina Taylor, Arif Awan, Terry Ng, Moira Rushton, Marie-France Savard, Lindsay Muyot, Marie Claude Reeves, Linda Hagerman, Hongbo Lui, Mark Bray, Dongsheng Tu, Lesley Seymour, Pierre-Olivier Gaudreau …
Authors
Hilton J; Cescon DW; Robinson A; Dhesy-Thind S; Taylor S; Awan A; Ng TL; Rushton M; Savard M-F; Muyot L
Journal
Cancer Research, Vol. 83, No. 5_Supplement,
Publisher
American Association for Cancer Research (AACR)
Publication Date
March 1, 2023
DOI
10.1158/1538-7445.sabcs22-p3-07-18
ISSN
0008-5472